OR WAIT 15 SECS
The company’s SLIM technology has been a part of the company’s accelerated growth by offering enhanced R&D analytics.
MOBILion Systems, a United States-based instrumentation company specializing in biomarker discovery, diagnostics, and therapeutic development, now offers its new ion mobility separations technology, structures for lossless ion manipulation (SLIM) for commercial use. SLIMS technology offers efficient separation, identification, and analysis of the most challenging, clinically significant molecules that other instruments fail to detect, the company announced in a July 22, 2020 press release highlighting its first-half 2020 progress.
“In the first half of 2020, our teams continue to implement [this technology] successfully, and the first-use cases of the SLIM technology are proving to be disruptive,” said Melissa Sherman, CEO of MOBILion Systems, in the company press release. “Despite COVID-19 we have hit all milestones and are being tapped by our beta users who want to use SLIM for COVID research. SLIM’s high resolution unlocks small structural differences that impact the research of the virus, the disease and its potential therapeutics.”
The SLIM technology can be integrated with liquid chromatography–mass spectrometry (LC–MS) workflows to provide more robust analytical information. For some applications, it can replace LC to provide higher resolution, speed, ease of use, and greater instrument uptime.
Source: MOBILion Systems